The U.S. Food and Drug Administration (FDA) has required application holders for all glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines to update product labelling with a warning about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss in one eye and may result in permanent visual impairment. The requirement was announced in an FDA Drug Safety Communication published on 9 November 2026. The requirement covers all FDA-approved GLP-1 RA products The FDA is requiring application holders to add information...